Relmada Therapeutics to Present at the 2015 Marcum MicroCap Conference

Description

Company Presentation on May 28, 2015 at 2:30 PM Eastern Time

NEW YORK, May 19, 2015 /PRNewswire/ — Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 2015 Marcum MicroCap Conference on Thursday, May 28, 2015 in New York City at the Grand Hyatt Hotel.

Relmada Therapeutics Corporate Logo

The presentation by Sergio Traversa, CEO of Relmada Therapeutics, is scheduled to begin at 2:30 p.m. ET. A live webcast of the presentation will be available through the Company's website at www.relmada.com. Please register at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived on the website for 90 days after the conference.

Members of the investment community who are interested in meeting with Relmada's management team during the conference event should contact Christine Silverstein, director of investor relations at Relmada Therapeutics, at (212) 702-7167 or csilverstein@relmada.com.

About the Marcum MicroCap Conference

The Marcum MicroCap Conference is dedicated to providing a forum where publicly traded companies under $500 million in market capitalization can network with the investment community. The conference features presentations by CEOs and CFOs from six principal industry sectors and provides investors with the opportunity to meet with management of these companies on a one-on-one basis. Industry sectors include Technology, Media & Internet; Software & Business Services; Life Science & Healthcare; Retail & Consumer Products; Energy & Natural Resources; and Industrials. The conference additionally includes a full agenda of panel discussions on issues of strategic importance to small cap issuers and investors, moderated by industry leaders.

The Marcum MicroCap Conference attracts fund managers and high net worth investors focusing on small cap equities. Over 2,000 participants from all segments of the microcap market attend each year, including senior management, finance and legal executives, venture and lower middle-market private equity investors, institutional investors, directors, investment bankers, buy- and sell-side analysts, and service providers to the microcap marketplace.

For complete information about the 2015 Marcum MicroCap Conference, visit www.marcumllp.com/microcap.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.

Forward-Looking Statements

This news release contains "forward-looking statements." These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact

Investor Contact:
Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Tel: 212-702-7169
mbecker@relmada.com

Media Contact:
David Salisbury
Berry & Company Public Relations
Tel: 212-253-8881
dsalisbury@berrypr.com

Logo – https://photos.prnewswire.com/prnh/20150113/168770LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-at-the-2015-marcum-microcap-conference-300085521.html

SOURCE Relmada Therapeutics, Inc.

Released May 19, 2015

Date Created

2015/05/19